Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 24, 2016. The report details a significant regulatory milestone for GSK's Vaccines portfolio, specifically the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Shingrix, a candidate vaccine for the prevention of shingles (herpes zoster) in adults aged 50 and over.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory announcement regarding product development rather than a financial results report.
Material Changes
The primary material change reported is the formal submission of the BLA for Shingrix to the FDA. This follows the completion of a comprehensive Phase III clinical trial program involving more than 37,000 subjects globally. The submission seeks approval for a two-dose intramuscular regimen with a two to six-month interval between doses.
Guidance, Outlook, and Risks
- Regulatory Outlook: Regulatory submissions for Shingrix in the European Union and Canada remain on track for 2016, with a planned submission for Japan in 2017.
- Clinical Data: The submission is supported by data from the ZOE-50 and ZOE-70 studies, published in the New England Journal of Medicine, demonstrating efficacy in reducing shingles incidence and postherpetic neuralgia (PHN).
- Future Studies: Additional trials are underway to evaluate revaccination in previously vaccinated individuals and to assess safety and immunogenicity in immunocompromised populations, including cancer patients and HIV-infected individuals.
- Risks: GSK includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections, referencing risk factors in the 2015 Form 20-F.
Key Facts for Investor Verification
- Confirmation of the FDA BLA submission date and specific indications approved (prevention of shingles in adults 50+).
- Timeline for regulatory decisions from the FDA, EMA (EU), and Health Canada.
- Commercial launch plans and pricing strategy for Shingrix upon approval.
- Results of ongoing trials in immunocompromised populations which could expand the addressable market.
- Impact of Shingrix on GSK's overall vaccine portfolio revenue projections.